Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  azacitidine
Find trials that include:  Any drugs shown
Results 1-25 of 54 for your search:
Start Over
Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission
Status: Active
Phase: Phase III
Type: Treatment
Age: 55 and over
Trial IDs: CC-486-AML-001, NCI-2013-00084, 2012-003457-28, NCT01757535
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 2215-CL-0301, NCI-2015-00931, 2015-000140-42, NCT02421939
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SGN33A-005, NCI-2016-00878, 2015-003482-28, NCT02785900
Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SGI-110-06, NCI-2017-00040, NCT02920008
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: M15-656, NCI-2017-00774, 2016-001466-28, NCT02993523
Azacitidine in Treating Patients Undergoing Matched Unrelated Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 201303012, NCI-2012-03105, NCT01747499
AC220 With 5-Aza or Low Dose Cytarabine
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Not specified
Trial IDs: 2012-1047, NCI-2013-02274, P50 CA100632, NCT01892371
Azacitidine and Romidepsin in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: AAAM3752, NCI-2014-00121, NCT01998035
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ARO-010, NCI-2015-01403, NCT02400281
Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: SGN33A-004, NCI-2016-00444, NCT02706899
A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AG-221-AML-005, NCI-2016-00454, NCT02677922
Ponatinib Hydrochloride with or without Azacitidine in Treating Patients with FLT3-mutated Acute Myeloid Leukemia
Status: Not yet active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-1083, NCI-2016-01187, NCT02829840
Azacitidine and Cyclophosphamide after Donor Stem Cell Transplantation in Preventing GVHD in Patients with Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Advanced Myelodysplastic Syndrome
Status: Active
Phase: Phase II, Phase I
Type: Prevention, Treatment
Age: 18 and over
Trial IDs: 201604081, NCI-2016-00582, NCT02750254
Avelumab and Azacitidine in Treating Patients with Refractory or Relapsed Acute Myeloid Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2016-0444, NCI-2016-01924, NCT02953561
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: INCB 24360-206 / ECHO-206, NCI-2017-00194, NCT02959437
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 60 and over
Trial IDs: BAML-16-001, NCI-2017-00278, NCT03013998
Azacitidine, Durvalumab, and Tremelimumab in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16-425, NCI-2017-00537, NCT03019003
Azacitidine and Sargramostim as Maintenance Therapy in Treating Patients with Poor-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome That Have Undergone Stem Cell Transplant or Received Cytarabine-Based Chemotherapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 6 months and older
Trial IDs: J1240, NCI-2014-01349, NA_00072223, NA_00072223_AM00039689, NCT01700673
Ruxolitinib Phosphate and Azacytidine in Treating Patients with Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0737, NCI-2013-00704, NCT01787487
Chemotherapy in Treating Patients with Myelodysplastic Syndrome before Donor Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 2661.00, NCI-2013-00538, 2661, NCT01812252
Start Over